{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:51:42Z","timestamp":1792763502834,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012551","name":"Sichuan Provincial Department of Science and Technology | Applied Basic Research Program of Sichuan Province","doi-asserted-by":"publisher","award":["2021YFS0375"],"award-info":[{"award-number":["2021YFS0375"]}],"id":[{"id":"10.13039\/100012551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011002","name":"National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund","doi-asserted-by":"publisher","award":["82003103"],"award-info":[{"award-number":["82003103"]}],"id":[{"id":"10.13039\/501100011002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For patients with advanced or metastatic Hepatocellular carcinoma (HCC) who are not suitable for surgical resection, systemic therapy has been considered to be the standard treatment. In recent years, a small subset of patients with unresectable HCC have been benefit from tyrosine kinase inhibitors (TKIs), and the overall survival time of these patients is significantly increased. However, all responders ultimately develop resistance to TKI treatment. The tripartite motif (TRIM) family member TRIM15 acts as an E3 ligase to mediate the polyubiquitination of substrates in cells. However, the biological role of TRIM15 in HCC is still an enigma. In our study, our results demonstrated that TRIM15 was abnormally upregulated in liver cancer cells after treated with TKIs and that this upregulation of TRIM15 contributed to TKI resistance in liver cancer cells. Then, we demonstrated that the upregulation of TRIM15 after TKI treatment was mediated by the AKT\/FOXO1 axis. Moreover, we demonstrated that TRIM15 induced the nuclear translocation of LASP1 by mediating its K63-linked polyubiquitination, which modulated sensitivity to TKIs by increasing the phosphorylation of AKT and the expression of Snail in liver cancer cells. Collectively, we identified a novel AKT\/FOXO1\/TRIM15\/LASP1 loop in cells, which provided potential candidates for overcoming TKI resistance in HCC.<\/jats:p>","DOI":"10.1038\/s41419-023-05577-7","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T21:06:41Z","timestamp":1674248801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["TRIM15 forms a regulatory loop with the AKT\/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs"],"prefix":"10.1038","volume":"14","author":[{"given":"Chong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6461-6005","authenticated-orcid":false,"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beichuan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9191-7708","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"5577_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"5577_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"5577_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"5577_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm.2018.06.14","volume":"6","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Kenerson HL, Pillarisetty VG, Riehle KJ, Yeung RS. Precision oncology in liver cancer. Ann Transl Med. 2018;6:285.","journal-title":"Ann Transl Med"},{"key":"5577_CR5","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1158\/0008-5472.CAN-21-0184","volume":"81","author":"HW Leung","year":"2021","unstructured":"Leung HW, Leung CON, Lau EY, Chung KPS, Mok EH, Lei MML, et al. EPHB2 activates beta-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res. 2021;81:3229\u201340.","journal-title":"Cancer Res"},{"key":"5577_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","volume":"142","author":"GL Beretta","year":"2017","unstructured":"Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017;142:271\u201389.","journal-title":"Eur J Med Chem"},{"key":"5577_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0681-z","volume":"9","author":"S Lu","year":"2018","unstructured":"Lu S, Yao Y, Xu G, Zhou C, Zhang Y, Sun J, et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis. 2018;9:646.","journal-title":"Cell Death Dis"},{"key":"5577_CR8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/1568009617666170427104356","volume":"17","author":"N Mir","year":"2017","unstructured":"Mir N, Jayachandran A, Dhungel B, Shrestha R, Steel JC. Epithelial-to-mesenchymal transition: a mediator of sorafenib resistance in advanced hepatocellular carcinoma. Curr Cancer Drug Targets. 2017;17:698\u2013706.","journal-title":"Curr Cancer Drug Targets"},{"key":"5577_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.","journal-title":"Signal Transduct Target Ther"},{"key":"5577_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-019-1177-0","volume":"38","author":"W Li","year":"2019","unstructured":"Li W, Dong X, He C, Tan G, Li Z, Zhai B, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2019;38:183.","journal-title":"J Exp Clin Cancer Res"},{"key":"5577_CR11","doi-asserted-by":"publisher","first-page":"166213","DOI":"10.1016\/j.bbadis.2021.166213","volume":"1867","author":"Y Sun","year":"2021","unstructured":"Sun Y, Ren D, Yang C, Yang W, Zhao J, Zhou Y, et al. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Biochim Biophys Acta Mol Basis Dis. 2021;1867:166213.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"5577_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00875-7","volume":"20","author":"M Liang","year":"2022","unstructured":"Liang M, Wang L, Sun Z, Chen X, Wang H, Qin L, et al. E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway. Cell Commun Signal. 2022;20:62.","journal-title":"Cell Commun Signal"},{"key":"5577_CR13","doi-asserted-by":"publisher","first-page":"e2100881","DOI":"10.1002\/advs.202100881","volume":"8","author":"W Xiong","year":"2021","unstructured":"Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. RRM2 regulates sensitivity to sunitinib and PD-1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway. Adv Sci. 2021;8:e2100881.","journal-title":"Adv Sci"},{"key":"5577_CR14","doi-asserted-by":"publisher","first-page":"e22191","DOI":"10.1096\/fj.202101507RR","volume":"36","author":"S Sofer","year":"2022","unstructured":"Sofer S, Lamkiewicz K, Armoza Eilat S, Partouche S, Marz M, Moskovits N, et al. A genome-wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi-kinase inhibitors in hepatocellular carcinoma cells. FASEB J. 2022;36:e22191.","journal-title":"FASEB J"},{"key":"5577_CR15","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.bbamcr.2011.06.002","volume":"1813","author":"G Tzivion","year":"2011","unstructured":"Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 2011;1813:1938\u201345.","journal-title":"Biochim Biophys Acta"},{"key":"5577_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"YJ Zhu","year":"2017","unstructured":"Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharm Sin. 2017;38:614\u201322.","journal-title":"Acta Pharm Sin"},{"key":"5577_CR17","doi-asserted-by":"publisher","first-page":"102007","DOI":"10.1016\/j.nano.2019.04.010","volume":"20","author":"D Suresh","year":"2019","unstructured":"Suresh D, Zambre A, Mukherjee S, Ghoshdastidar S, Jiang Y, Joshi T, et al. Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR\/EMT pathway and stimulates p53 for TKI sensitization in NSCLC. Nanomedicine. 2019;20:102007.","journal-title":"Nanomedicine"},{"key":"5577_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-022-00581-z","volume":"17","author":"R Yuan","year":"2022","unstructured":"Yuan R, Fan Q, Liang X, Han S, He J, Wang QQ, et al. Cucurbitacin B inhibits TGF-beta1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K\/Akt\/mTOR pathways. Chin Med. 2022;17:24.","journal-title":"Chin Med"},{"key":"5577_CR19","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1158\/0008-5472.CAN-10-4058","volume":"71","author":"P Gulhati","year":"2011","unstructured":"Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011;71:3246\u201356.","journal-title":"Cancer Res"},{"key":"5577_CR20","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1158\/0008-5472.CAN-11-2055","volume":"72","author":"R Chen","year":"2012","unstructured":"Chen R, Yang Q, Lee JD. BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt\/GSK3beta signaling pathway. Cancer Res. 2012;72:1579\u201387.","journal-title":"Cancer Res"},{"key":"5577_CR21","doi-asserted-by":"publisher","first-page":"75102","DOI":"10.18632\/oncotarget.20527","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Liu Y, Fan C, Wang L, Li A, Zhou H, et al. Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway. Oncotarget. 2017;8:75102\u201313.","journal-title":"Oncotarget"},{"key":"5577_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0443-y","volume":"9","author":"Q Gao","year":"2018","unstructured":"Gao Q, Tang L, Wu L, Li K, Wang H, Li W, et al. LASP1 promotes nasopharyngeal carcinoma progression through negatively regulation of the tumor suppressor PTEN. Cell Death Dis. 2018;9:393.","journal-title":"Cell Death Dis"},{"key":"5577_CR23","doi-asserted-by":"publisher","first-page":"5277409","DOI":"10.1155\/2021\/5277409","volume":"2021","author":"Q Xue","year":"2021","unstructured":"Xue Q, Jiang H, Wang J, Wei D. LASP1 induces epithelial-mesenchymal transition in lung cancer through the TGF-beta1\/Smad\/Snail pathway. Can Respir J. 2021;2021:5277409.","journal-title":"Can Respir J"},{"key":"5577_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41556-021-00732-8","volume":"23","author":"G Zhu","year":"2021","unstructured":"Zhu G, Herlyn M, Yang X. TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. Nat Cell Biol. 2021;23:978\u201391.","journal-title":"Nat Cell Biol"},{"key":"5577_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1248\/bpb.b19-01097","volume":"43","author":"K Hosokawa","year":"2020","unstructured":"Hosokawa K, Ishimaru H, Watanabe T, Fujimuro M. The lysosome pathway degrades CD81 on the cell surface by poly-ubiquitination and clathrin-mediated endocytosis. Biol Pharm Bull. 2020;43:540\u20135.","journal-title":"Biol Pharm Bull"},{"key":"5577_CR26","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1359\/jbmr.1997.12.9.1396","volume":"12","author":"BJ Votta","year":"1997","unstructured":"Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Min Res. 1997;12:1396\u2013406.","journal-title":"J Bone Min Res"},{"key":"5577_CR27","doi-asserted-by":"publisher","first-page":"107990","DOI":"10.1016\/j.celrep.2020.107990","volume":"32","author":"M Liu","year":"2020","unstructured":"Liu M, Yan M, Lv H, Wang B, Lv X, Zhang H, et al. Macrophage K63-linked ubiquitination of YAP promotes its nuclear localization and exacerbates atherosclerosis. Cell Rep. 2020;32:107990.","journal-title":"Cell Rep"},{"key":"5577_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fonc.2018.00391","volume":"8","author":"E Butt","year":"2018","unstructured":"Butt E, Raman D. New frontiers for the cytoskeletal protein LASP1. Front Oncol. 2018;8:391.","journal-title":"Front Oncol"},{"key":"5577_CR29","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/onc.2015.166","volume":"35","author":"N Duvall-Noelle","year":"2016","unstructured":"Duvall-Noelle N, Karwandyar A, Richmond A, Raman D. LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex. Oncogene. 2016;35:1122\u201333.","journal-title":"Oncogene"},{"key":"5577_CR30","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006;66:11851\u20138.","journal-title":"Cancer Res"},{"key":"5577_CR31","first-page":"9377","volume":"15","author":"H Zhang","year":"2018","unstructured":"Zhang H, Wang Q, Liu J, Cao H. Inhibition of the PI3K\/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. Oncol Lett. 2018;15:9377\u201384.","journal-title":"Oncol Lett"},{"key":"5577_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","volume":"329","author":"H van Malenstein","year":"2013","unstructured":"van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion, and risk of rebound growth. Cancer Lett. 2013;329:74\u201383.","journal-title":"Cancer Lett"},{"key":"5577_CR33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2174\/15680096113136660102","volume":"13","author":"Y Wang","year":"2013","unstructured":"Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 2013;13:963\u201372.","journal-title":"Curr Cancer Drug Targets"},{"key":"5577_CR34","doi-asserted-by":"publisher","first-page":"108754","DOI":"10.1016\/j.abb.2021.108754","volume":"699","author":"H Zhao","year":"2021","unstructured":"Zhao H, Cheng X, Yu J, Li Y. Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells. Arch Biochem Biophys. 2021;699:108754.","journal-title":"Arch Biochem Biophys"},{"key":"5577_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02963-7","volume":"19","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wang L, Wang S, Chen X, Liang M, Zhang X, et al. CHN1 promotes epithelial-mesenchymal transition via the Akt\/GSK-3beta\/Snail pathway in cervical carcinoma. J Transl Med. 2021;19:295.","journal-title":"J Transl Med"},{"key":"5577_CR36","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.7150\/jca.39671","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Li J, Long X, Jiao L, Zhou M, Wu K. MRPS16 facilitates tumor progression via the PI3K\/AKT\/Snail signaling axis. J Cancer. 2020;11:2032\u201343.","journal-title":"J Cancer"},{"key":"5577_CR37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.15252\/embj.201695534","volume":"36","author":"CW Pan","year":"2017","unstructured":"Pan CW, Jin X, Zhao Y, Pan Y, Yang J, Karnes RJ, et al. AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction. EMBO J. 2017;36:995\u20131010.","journal-title":"EMBO J"},{"key":"5577_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.neo.2021.11.002","volume":"23","author":"W Huang","year":"2021","unstructured":"Huang W, Chen K, Lu Y, Zhang D, Cheng Y, Li L, et al. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. Neoplasia. 2021;23:1227\u201339.","journal-title":"Neoplasia"},{"key":"5577_CR39","first-page":"785","volume":"42","author":"D Yan","year":"2019","unstructured":"Yan D, Yan X, Dai X, Chen L, Sun L, Li T, et al. Activation of AKT\/AP1\/FoxM1 signaling confers sorafenib resistance to liver cancer cells. Oncol Rep. 2019;42:785\u201396.","journal-title":"Oncol Rep"},{"key":"5577_CR40","doi-asserted-by":"publisher","first-page":"110210","DOI":"10.1016\/j.cellsig.2021.110210","volume":"91","author":"M Roy","year":"2022","unstructured":"Roy M, Singh K, Shinde A, Singh J, Mane M, Bedekar S, et al. TNF-alpha-induced E3 ligase, TRIM15 inhibits TNF-alpha-regulated NF-kappaB pathway by promoting turnover of K63 linked ubiquitination of TAK1. Cell Signal. 2022;91:110210.","journal-title":"Cell Signal"},{"key":"5577_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.7150\/jca.27856","volume":"10","author":"X Han","year":"2019","unstructured":"Han X, Huang C, Qu X, Liu S, Yang X, Wang Y, et al. Tripartite motif-containing 15 overexpression in non-small cell lung cancer is associated with poor patient prognoses. J Cancer. 2019;10:843\u201352.","journal-title":"J Cancer"},{"key":"5577_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10863-021-09872-w","volume":"53","author":"L Zhang","year":"2021","unstructured":"Zhang L, Qin B, Zou B, Wang S, Quan X, Wang J, et al. Knockdown of TRIM15 inhibits the proliferation, migration, and invasion of esophageal squamous cell carcinoma cells through inactivation of the Wnt\/beta-catenin signaling pathway. J Bioenerg Biomembr. 2021;53:213\u201322.","journal-title":"J Bioenerg Biomembr"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05577-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:50:16Z","timestamp":1674262216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05577-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["5577"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-05577-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki principles. It was approved by the Animal Use and Care Committees at the Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects have written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"47"}}